Journal
MUSCLE & NERVE
Volume 39, Issue 6, Pages 849-850Publisher
WILEY
DOI: 10.1002/mus.21306
Keywords
adverse effect; autoimmune disease; CellCept; myasthenia gravis; mycophenolate mofetil
Categories
Ask authors/readers for more resources
Immunosuppressive therapies are critical in the management of numerous conditions including myasthenia gravis. Mycophenolate mofetil is a widely used, oral immunosuppressive agent that is considered to have few adverse effects compared with similar drugs. We report the case of a patient who developed T-cell lymphoproliferative lesions following long-term treatment with mycophenolate mofetil and prednisone for myasthenia gravis. The lesions resolved following cessation of the treatment. This case highlights a serious complication of a commonly used drug. Muscle Nerve 39: 849-850, 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available